54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives

Bone Biology, Remodeling & Pathophysiology of Bone Loss

Bone is a metabolically dynamic, mineralized connective tissue undergoing continuous remodeling throughout adult life. Remodeling occurs in localized anatomical structures termed basic multicellular units (BMUs), replacing old micro-damaged bone with newly synthesized matrix to maintain biomechanical strength and calcium homeostasis.

The Cellular Remodeling Cycle

1. Osteoclasts (Bone Resorption):
   • Multinucleated giant cells derived from hematopoietic monocyte-macrophage precursors.
   • Osteoclasts adhere to bone surfaces via alpha-v-beta-3 integrins, forming an isolated sealing zone. They secrete hydrogen ions via an apical vacuolar H+-ATPase proton pump to dissolve hydroxyapatite ($\text{Ca}_{10}[\text{PO}_4]_6[\text{OH}]_2$) and release cathepsin K to degrade type I collagen and bone matrix proteins.
2. Osteoblasts (Bone Formation):
   • Mononuclear cells derived from mesenchymal stem cells under the regulation of the Runx2/Cbfa1 and Wnt/beta-catenin signaling pathways.
   • Osteoblasts synthesize and secrete osteoid (unmineralized organic matrix composed of 90% type I collagen) and coordinate subsequent mineral crystallization through alkaline phosphatase activity.
3. Osteocytes (The Mechanosensing Network):
   • Terminally differentiated osteoblasts entrapped within calcified lacunae, forming an extensive canalicular communication network.
   • Osteocytes detect mechanical strain and fluid shear stress, orchestrating remodeling by modulating paracrine signals.
   • In the absence of mechanical loading, osteocytes secrete sclerostin (encoded by the SOST gene), which binds to LRP5/6 receptors, inhibiting Wnt/beta-catenin signaling and shutting down osteoblast bone synthesis.

                  THE RANK / RANKL / OSTEOPROTEGERIN (OPG) AXIS

     Osteoblast / Stromal Precursors                     Osteoclast Precursors
               │                                                  │
               ▼                                                  ▼
   Expresses RANK Ligand (RANKL) ════════════════════════► RANK Receptor
               │                                                  │
               │ [Inhibited by OPG]                               ▼
               ▼                                         Osteoclast Maturation,
    Secretes Osteoprotegerin (OPG)                       Activation, Survival
    (Soluble Decoy Receptor for RANKL)                            │
               │                                                  ▼
               ▲                                        Bone Resorption & Matrix
               │ [Stimulated by Estrogen]               Dissolution (Cathepsin K)
         ESTROGEN

The Impact of Postmenopausal Estrogen Deficiency

• Under normal physiological conditions, estrogen downregulates osteoclastogenesis by: (1) stimulating osteoblasts to produce osteoprotegerin (OPG), a soluble decoy receptor that binds and neutralizes RANKL, (2) suppressing pro-inflammatory cytokines (IL-1, IL-6, TNF-α) that promote osteoclast recruitment, and (3) directly inducing osteoclast apoptosis.
• At menopause, cessation of ovarian 17-beta-estradiol synthesis leads to unchecked RANKL signaling. The balance tips dramatically in favor of osteoclastic bone resorption:
  • Rapid phase of bone loss: 2% to 3% annual loss of trabecular bone during the first 5 to 8 years following menopause.
  • Architectural consequence: Trabecular plates become thinned, perforated, and disconnected, resulting in irreversible microarchitectural deterioration that markedly increases skeletal fragility out of proportion to bone density measurements alone.
• Age-Related (Senile) Bone Loss: Beginning in the fourth decade, both men and women experience progressive decline in osteoblast synthetic capacity, blunted Wnt signaling, decreased dermal synthesis of vitamin D, intestinal calcium malabsorption, and secondary hyperparathyroidism, which primarily affects cortical bone thickness and porosity.

---

Screening Guidelines: USPSTF & National Consensus

Fragility fractures are silent until clinical trauma occurs. Universal and risk-targeted screening identifies individuals at elevated fracture risk before initial fracture presentation.

USPSTF Screening Recommendations (Grade B)

• All Women Aged ≥65 Years: Routine screening for osteoporosis with Dual-Energy X-ray Absorptiometry (DEXA) of the hip and lumbar spine is recommended without requiring clinical risk scoring.
• Postmenopausal Women Aged <65 Years: Screening is recommended if their calculated 10-year fracture risk equals or exceeds that of a 65-year-old white female with no additional risk factors.
  • This threshold corresponds to a 10-year Major Osteoporotic Fracture (MOF) probability of ≥8.4% calculated via the US FRAX tool without bone mineral density (BMD).
  • Alternatively, simple clinical risk assessment instruments such as the Osteoporosis Screening Tool (OST) (calculated as $\text{OST} = [\text{Weight in kg} - \text{Age in years}] / 5$) can be used; an OST score ≤1 indicates high risk warranting DEXA.

Screening in Men

While the USPSTF concludes that current evidence is insufficient to assess the balance of benefits and harms of routine screening in men (Grade I), the Endocrine Society, National Osteoporosis Foundation (NOF / BHOF), and American College of Physicians (ACP) recommend:

• All Men Aged ≥70 Years: Consideration of DEXA screening.
• Men Aged 50 to 69 Years: DEXA screening is indicated if clinical risk factors are present:
  • Prolonged systemic corticosteroid therapy (≥5 mg/day of prednisone equivalent for ≥3 months)
  • Androgen deprivation therapy (ADT) for prostate cancer or primary/secondary hypogonadism
  • Prior low-trauma fragility fracture
  • Primary hyperparathyroidism, hyperthyroidism, or celiac disease
  • History of chronic alcohol abuse (≥3 drinks daily) or heavy smoking

---

Diagnostic Modalities: DEXA, T-Scores, Z-Scores & FRAX

Dual-Energy X-ray Absorptiometry (DEXA)

DEXA is the diagnostic gold standard for measuring areal Bone Mineral Density (BMD in g/cm²). Two low-dose X-ray beams of differing energy levels pass through tissue, allowing subtraction of soft tissue attenuation from calcified bone.

• Anatomical Scan Sites: Posteroanterior (PA) lumbar spine (L1–L4), femoral neck, total hip, and the 33% (distal one-third) radius of the non-dominant forearm. The distal radius is specifically evaluated when the hip or spine cannot be accurately assessed (e.g., severe degenerative osteoarthritis, severe scoliosis, bilateral hip arthroplasties) or in cases of primary hyperparathyroidism (which selectively resorbs cortical bone).

                  T-SCORE VERSUS Z-SCORE COMPARISON

   Parameter          T-Score                                     Z-Score
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════
   Reference Pop.     Young, healthy sex-matched reference         Age-, sex-, and ethnicity-matched
                      population at peak bone mass (age 20-29)     reference population

   Target Population  • Postmenopausal women                      • Premenopausal women
                      • Men aged ≥50 years                        • Men aged <50 years
                                                                  • Children and adolescents

   WHO Diagnostic     • Normal: T-score ≥ -1.0                    • Within expected range for age: Z-score > -2.0
   Cutoffs            • Osteopenia: -1.0 > T-score > -2.5         • Below expected range for age: Z-score ≤ -2.0
                      • Osteoporosis: T-score ≤ -2.5                (Prompts evaluation for secondary osteoporosis)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════

[!CAUTION] DEGENERATIVE ARTIFACTS AT THE LUMBAR SPINE In patients over age 65, extensive degenerative disc disease, osteophytes, vertebral compression fractures, aortic calcifications, and facet joint osteoarthritis add artificial radiodense calcium within the DEXA beam path. This falsely elevates the lumbar spine T-score, masking severe osteoporosis. In such cases, the femoral neck, total hip, or 33% radius T-score provides the accurate diagnostic assessment.

Clinical Diagnosis of Osteoporosis: Fragility Fractures

Osteoporosis is a clinical diagnosis that does not rely solely on DEXA T-scores. A patient who experiences a fragility fracture (defined as a fracture sustained from low-energy trauma, such as a fall from standing height or less, excluding the skull, cervical spine, hands, feet, and ankles) has a definitive clinical diagnosis of osteoporosis regardless of DEXA T-score. Common fragility fracture sites include:

1. Vertebral Compression Fractures: Often clinically silent; may present as progressive loss of height (≥1.5 inches historically or ≥0.8 inches prospectively) or thoracic kyphosis ("dowager's hump").
2. Femoral Neck / Intertrochanteric Hip Fractures: Associated with 20% to 30% all-cause mortality within 1 year and permanent loss of independent ambulation in >50% of survivors.
3. Distal Radius (Colles) Fractures: Often the earliest clinical harbinger of skeletal fragility in perimenopausal women.

The FRAX Fracture Risk Assessment Tool

The WHO Fracture Risk Assessment Tool (FRAX) integrates 11 clinical risk factors with femoral neck BMD to calculate the 10-year probability of a Major Osteoporotic Fracture (MOF: composite of clinical spine, hip, forearm, or proximal humerus fracture) and the 10-year probability of Hip Fracture alone.

• Incorporated Clinical Risk Factors:
  • Age (40 to 90 years), sex, weight, height
  • Prior fragility fracture as an adult
  • Parental history of hip fracture (a powerful independent genetic predictor)
  • Current cigarette smoking
  • Systemic glucocorticoid exposure (≥5 mg prednisone equivalent daily for ≥3 months)
  • Confirmed Rheumatoid Arthritis (the only disease explicitly weighted in FRAX)
  • Secondary osteoporosis etiologies (type 1 diabetes, osteogenesis imperfecta, hyperthyroidism, hypogonadism, chronic malabsorption)
  • Alcohol intake ≥3 units per day
  • Femoral neck BMD (optional; FRAX can calculate baseline risk without BMD for screening)

Treatment Indications (BHOF / NOF Guidelines)

Pharmacologic intervention is indicated in postmenopausal women and men aged ≥50 years who meet any of the following four criteria:

1. A documented hip or vertebral fragility fracture (clinical or asymptomatic radiographic fracture).
2. A DEXA T-score ≤ -2.5 at the femoral neck, total hip, lumbar spine, or 33% radius.
3. Low bone mass (Osteopenia: T-score between -1.0 and -2.5) AND a 10-year FRAX probability of Major Osteoporotic Fracture ≥20%.
4. Low bone mass (Osteopenia: T-score between -1.0 and -2.5) AND a 10-year FRAX probability of Hip Fracture ≥3%.

---

Pharmacotherapy: Antiresorptive & Anabolic Agents

                  OSTEOPOROSIS PHARMACOTHERAPY SPECTRUM

   Class              Drug & Route                     Dosing Schedule            Key Clinical Considerations
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Oral               Alendronate (Fosamax)            70 mg PO once weekly       Take with 8 oz plain water; upright x 30 min;
   Bisphosphonates    Risedronate (Actonel)            35 mg PO once weekly       Contraindicated if eGFR <30-35 or esophageal disease

   IV                 Zoledronic Acid (Reclast)        5 mg IV once yearly        Acute-phase reaction (flu-like) in ~30%;
   Bisphosphonates                                     (Infuse over ≥15 min)      Pre-treat with acetaminophen; avoid if eGFR <35

   RANKL              Denosumab (Prolia)               60 mg SC every 6 months    Safe in CKD; NO RENAL DOSE ADJUSTMENT;
   Inhibitor                                                                      CRITICAL: Stopping causes rebound vertebral fractures!

   PTH / PTHrP        Teriparatide (Forteo)            20 mcg SC once daily       Anabolic bone-builder; max 2 years lifetime;
   Analogues          Abaloparatide (Tymlos)           80 mcg SC once daily       Follow immediately with antiresorptive to retain bone

   Sclerostin         Romosozumab (Evenity)            210 mg SC once monthly     Dual action: stimulates formation, inhibits resorption;
   Inhibitor                                           (2 prefilled syringes x12m) Boxed warning: Avoid if MI or stroke within 1 year
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Bisphosphonates (First-Line Antiresorptive Therapy)

• Mechanism: Synthetic analogues of pyrophosphate that bind with high affinity to hydroxyapatite crystals in active bone remodeling sites. During resorption, osteoclasts endocytose the drug, which inhibits farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway. This prevents prenylation of small GTPases essential for osteoclast ruffled border maintenance, cytoskeletal organization, and survival, directly inducing osteoclast apoptosis.
• Oral Administration Instructions:
  • Oral bioavailability of bisphosphonates is exceedingly poor (<1%). Ingesting any food, calcium, coffee, or juice completely prevents systemic absorption.
  • Must be taken first thing in the morning upon awakening, on an entirely empty stomach, with a full 8-ounce glass of plain tap water (not mineral water or sparkling water).
  • The patient must remain strictly upright (sitting upright, standing, or walking) for at least 30 minutes (60 minutes for oral ibandronate) and ingest no food, other liquids, or other oral medications for at least 30 to 60 minutes.
• Contraindications:
  • Esophageal disorders that delay emptying (e.g., severe achalasia, esophageal strictures)
  • Inability to sit or stand upright for at least 30 minutes
  • Severe renal impairment: eGFR <35 mL/min for alendronate and zoledronic acid; eGFR <30 mL/min for risedronate and ibandronate
  • Uncorrected hypocalcemia
• Intravenous Zoledronic Acid (5 mg IV annually): Bypasses the gastrointestinal tract, ensuring 100% adherence. An acute-phase flu-like reaction (low-grade fever, arthralgias, myalgias) occurs in up to one-third of patients within 24 to 72 hours of the first infusion; incidence drops sharply with subsequent infusions. Prophylactic administration of oral acetaminophen substantially blunts symptoms.
• Bisphosphonate 'Drug Holiday' Strategy:
  • Bisphosphonates incorporate into the skeletal matrix with a biological elimination half-life exceeding 10 years, providing sustained antiresorptive protection even after drug discontinuation.
  • Reassess fracture risk after 5 years of oral bisphosphonate (or 3 years of IV zoledronic acid):
    • Low to Moderate Risk (T-score > -2.5 and no incident fractures): Initiate a drug holiday for 2 to 3 years. Monitor serial DEXA every 1 to 2 years and restart therapy if BMD declines significantly or a fracture occurs.
    • High Risk (Persistent hip T-score ≤ -2.5, advanced age, or prior hip/vertebral fracture): Continue oral therapy up to 10 years (or IV zoledronic acid up to 6 years) or consider transitioning to an anabolic agent.
• Rare Adverse Effects Associated with Prolonged Suppression:
  • Atypical Femur Fractures (AFF): Non-comminuted transverse or short oblique fractures located in the subtrochanteric region or femoral shaft, characterized by localized lateral cortical thickening/beaking. Patients typically report prodromal dull, aching groin or thigh pain for weeks to months before complete fracture. If prodromal thigh pain occurs, order bilateral full-length femur radiographs immediately and discontinue bisphosphonates.
  • Osteonecrosis of the Jaw (ONJ): Exposed, necrotic bone in the maxillofacial region persisting for >8 weeks in patients with no history of radiation therapy. Associated with invasive dentoalveolar surgery (tooth extractions, dental implants). A comprehensive oral exam and necessary dental extractions should be completed before starting antiresorptive therapy.

2. RANK Ligand Inhibitor: Denosumab (Prolia)

• Mechanism: A fully human IgG2 monoclonal antibody that binds with high affinity and specificity to RANKL, preventing it from activating RANK on osteoclast surfaces, completely shutting down osteoclast formation, function, and survival.
• Dosing: 60 mg subcutaneous injection administered once every 6 months.
• Renal Safety: Unlike bisphosphonates, denosumab is not cleared by the kidneys (cleared by the reticuloendothelial system); it is safe to use in chronic kidney disease, including stage 4 and 5 CKD and dialysis. However, patients with severe renal impairment are at high risk for severe, life-threatening hypocalcemia; baseline calcium and vitamin D levels must be replete before each dose.

[!CAUTION] THE DENOSUMAB DISCONTINUATION REBOUND CATASTROPHE Denosumab does not incorporate into the bone matrix. When a dose is missed or discontinued, its inhibitory effect vanishes rapidly, triggering a massive rebound surge in osteoclastogenesis and bone turnover. Within 6 to 12 months after stopping denosumab, BMD declines rapidly to baseline or below, accompanied by a high risk of multiple spontaneous vertebral fractures (rebound vertebral fracture cascade). Denosumab should NEVER be stopped without immediately transitioning to a bisphosphonate (e.g., initiating oral alendronate or IV zoledronic acid 6 months after the final denosumab injection) to lock in bone density gains.

3. Anabolic (Bone-Forming) Agents

• Teriparatide (Forteo; recombinant human PTH 1-34) & Abaloparatide (Tymlos; synthetic PTHrP 1-34 analogue):
  • Intermittent daily subcutaneous pulse administration preferentially stimulates osteoblast bone formation over osteoclast resorption, increasing trabecular bone volume and cortical thickness.
  • Indicated for patients with very high fracture risk (e.g., T-score ≤ -3.0, multiple prior fragility fractures, or failure/fractures on antiresorptive therapy).
  • Limited to a maximum cumulative duration of 2 years (24 months) in a patient's lifetime. When the 2-year anabolic course is completed, the patient MUST immediately be transitioned to an antiresorptive agent (bisphosphonate or denosumab); otherwise, newly formed mineralized bone is rapidly resorbed.
  • Contraindicated in patients with Paget's disease of bone, unexplained alkaline phosphatase elevation, prior external beam radiation therapy involving the skeleton, bone metastases, or primary hyperparathyroidism.
• Romosozumab (Evenity; Sclerostin Inhibitor):
  • Monoclonal antibody that neutralizes sclerostin, producing a dual effect: strongly stimulates bone formation while simultaneously decreasing bone resorption.
  • Administered as 210 mg SC monthly (two 105 mg injections) for exactly 12 months, followed by an antiresorptive agent.
  • FDA Boxed Warning: Romosozumab increases the risk of myocardial infarction, stroke, and cardiovascular death. It must NOT be initiated in patients who have experienced a myocardial infarction or stroke within the preceding year.

---

Lifestyle Counseling, Calcium, Vitamin D & Fall Prevention

• Elemental Calcium Requirements:
  • 1,000 mg daily for men aged 50 to 70 years.
  • 1,200 mg daily for women aged ≥51 years and men aged ≥71 years.
  • Dietary Preferred: Dietary calcium (dairy products, fortified plant milks, canned salmon/sardines with bones, dark leafy greens) is the preferred source. High-dose calcium supplements (boluses >500 mg at once) may elevate transient serum calcium spikes, which have been implicated in nephrolithiasis and vascular calcification.
• Vitamin D Requirements:
  • 800 to 1,000 IU daily of Cholecalciferol (Vitamin D3) for adults aged ≥50 years, targeting a serum 25-hydroxyvitamin D level of ≥30 ng/mL (75 nmol/L).
• Physical Exercise:
  • Regular weight-bearing exercise (e.g., brisk walking, stair climbing) and progressive resistance training improve skeletal loading, enhance balance, and maintain muscle mass (sarcopenia prevention).
• Multifactorial Fall Prevention:
  • Over 95% of hip fractures result from a direct fall. Primary care fall risk assessment includes:
    • Reviewing and deprescribing fall-risk-increasing drugs (sedative-hypnotics, benzodiazepines, anticholinergics, tricyclic antidepressants, and excessive antihypertensives causing orthostatic hypotension).
    • Correcting visual acuity and cataracts.
    • Home environment hazard mitigation: removing throw rugs, improving stair lighting, installing bathroom grab bars and non-skid shower mats.
    • Referral to physical therapy for balance, gait, and core stability training (e.g., Tai Chi).